Serum Activin A is not associated with carcinoid heart disease (CHD) in patients with neuroendocrine tumors (NET)

#3475

Introduction: CHD is a fibrotic cardiac disorder that is caused by serotonin secreted by NET, especially in the presence of liver metastases. Currently, N terminal pro B type natriuretic peptide (NT-proBNP) is used to detect cardiac damage due to CHD, yet no predictive biomarkers are available. Activin A has been identified as a potential biomarker for CHD.

Aim(s): This study investigated the potential of Activin A to detect or predict CHD in serum of patients (pts) with NET.

Materials and methods: Pts were divided in CHD+ and CHD-. When available, two timepoints were included: T=0: liver metastasis without CHD for all pts. T=1: CHD+: confirmed CHD, CHD-: Confirmed absence of CHD, ≥5 years after liver metastases. Activin A, NT-proBNP and serotonin were measured in all pts. Area under the curve (AUC) was used for detection of CHD with Activin A and NT-proBNP. Logrank test was used for comparison of survival.

Conference:

Presenting Author: Levy S

Authors: Levy S, Kilgallen A, Korse C, Oerlemans M, Sluijter J,

Keywords: CHD, carcinoid heart disease, biomarker, NT-proBNP, Activin A,